Please login to the form below

Not currently logged in
Email:
Password:

GSK benefiting from joint R&D

GlaxoSmithKline and Pozen announced on April 17 that the US Food and Drug Administration has approved the migraine medication Treximet
GlaxoSmithKline (GSK) and Pozen announced on April 17 that the US Food and Drug Administration (FDA) has approved the migraine medication Treximet.

Treximet has been developed to treat migraine and could be available in the US market as early as mid-May 2008. Trials into the drug have shown it to be more effective than sumatriptan and naproxen, two existing migraine medications, both of which are components of Treximet.

More than 3,700 migraine patients have been involved in extensive clinical trials that saw Treximet used to treat almost 30,000 migraine attacks.

Dr Stephen Silberstein, professor of neurology and director of the Jefferson Headache Centre at Thomas Jefferson University, said: "The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Treximet produced sustained migraine pain relief for a significant number of patients."

"Migraine patients want their medicine to work early and to continue to provide relief," he added.

GSK has also announced an alliance with Regulus Therapeutics to launch an R&D programme to discover novel microRNA-targeted therapeutics for treating inflammatory conditions, such as rheumatoid arthritis and bowel disease. Regulus will be given a $20m upfront payment as part of the deal.

17th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics